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A B S T R A C T   
Human naïve pluripotent stem cells (PSCs) represent an optimal homogenous starting point for molecular in-
terventions and differentiation strategies. This is in contrast to the standard primed PSCs which fluctuate in 
identity and are transcriptionally heterogeneous. However, despite many efforts, the maintenance and expansion 
of human naïve PSCs remains a challenge. Here, we discuss our recent strategy for the stabilization of human PSC 
in the naïve state based on the use of a single chemical inhibitor of the related kinases CDK8 and CDK19. These 
kinases phosphorylate and negatively regulate the multiprotein Mediator complex, which is critical for enhancer- 
driven recruitment of RNA Pol II. The net effect of CDK8/19 inhibition is a global stimulation of enhancers, 
which in turn reinforces transcriptional programs including those related to cellular identity. In the case of 
pluripotent cells, the presence of CDK8/19i efficiently stabilizes the naïve state. Importantly, in contrast to 
previous chemical methods to induced the naïve state based on the inhibition of the FGF-MEK-ERK pathway, 
CDK8/19i-naïve human PSCs are chromosomally stable and retain developmental potential after long-term 
expansion. We suggest this could be related to the fact that CDK8/19 inhibition does not induce DNA deme-
thylation. These principles may apply to other fate decisions.   
1. A new approach to human pluripotency 
Human embryonic pluripotent stem cells (PSCs) provide a chal-
lenging parallel to our understanding of pluripotency based in rodents. 
The extent to which human PSCs can be captured in a stable naïve state, 
its similarity to rodent naïve pluripotency, and even its clinical useful-
ness, remain in question [1–3]. Inhibition of the FGF-MEK-ERK signaling 
pathway is central to naïve pluripotency across multiple mammalian 
species, however the application of this in culture media appears to 
require species-specific adaptations to avoid genomic instability [4–7]. 
Understanding the mechanisms by which MEK-inhibition leads to the 
transition from primed to naïve pluripotency remains in progress. 
The Mediator complex operates at enhancers and is a pivotal 
orchestrator of the transcriptional program of cell identity [8,9] (Fig. 1). 
Moreover, several data suggest that Mediator function may lie down-
stream of the MEK-ERK pathway (see below). Indeed, we recently 
identified an important role for the Mediator complex in stabilizing 
naïve pluripotency both in mouse and human PSCs, which recapitulates 
many aspects of MEK-inhibition [10]. In this review, we introduce the 
role of Mediator in cell identity, in particular during pluripotency, and 
we summarize our recent report of a pharmacological strategy for the 
manipulation of Mediator that stabilizes the naïve state in mouse, 
human, and non-human primate PSCs [10]. We also discuss the impli-
cations for other states of cellular plasticity beyond pluripotency, and its 
application in directing the resolution of cellular fate decisions. 
2. Enhancers, super-enhancers, and cell identity 
Each cell-type contains a unique repertoire of active enhancer 
complexes at specific DNA regions, which arise by high concentration of 
lineage-specific transcription factors [11–14]. Collectively, the tran-
scription factors, associated chromatin regulators, and the epigentic 
marks that they generate, serve as the platform to recruit a single large 
multi-protein complex known as Mediator [8,9,15] (Fig. 1). In a sense, 
the diverse combinatorial information input present at enhancers is 
reduced into a single output, namely, the Mediator complex, which 
thereby can be considered the universal transducer of enhancers. The 
main function of Mediator is, in turn, the recruitment of RNA poly-
merase II (RNA Pol II) to nearby and distant promoters, thus having a 
major contribution to the transcriptional program characteristic of each 
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cell type [8,9,13,16] (Fig. 1). 
Super-enhancers (SEs) constitute a relatively novel concept that re-
fers to a small fraction of unusually large and powerful enhancers [12, 
13]. SE’s are multipartite, as they arise by coallescing clusters of smaller 
typical enhancer constituents in close proximity, and these large ag-
gregates display emergent properties that distinguish them functionally 
from the smaller typical enhancers (TEs) [17] (Fig. 1). In particular, SEs 
are extraordinarily potent in driving transcription and they rely on 
phase separation to confer their stability and flexibility to change [17]. 
Interestingly, the most influential genes determining cell identity are 
often found under the control of SEs [11–13]. SEs drive high expression 
of master transcription factors, which in turn, enrich within the 
enhancer loci, completing a positive-feedback loop and establishing the 
regulatory network that maintains cell identity [11–13]. In agreement 
with its critical role in recruiting RNA Pol II, Mediator is highly abun-
dant at SEs [13] and therefore, we reasoned that it could be an action-
able point to manipulate SEs and cell identity (Fig. 1). Below, we 
summarize the current understanding of Mediator function, and regu-
lation by CDK8 and CDK19 kinases (abbreviated as CDK8/19). 
3. Mediator: a bridge between enhancers and promoters 
There have been great advances in recent years regarding the 
structure and mechanistic functioning of Mediator [8,9,15,18–20]. The 
30 subunits of Mediator are organized in four general domains: the 
“head”, “middle”, and “tail” domains that constitute “core-Mediator”, 
plus a fourth accessory domain known as the “CDK8/19-module” 
(Fig. 1). The Mediator tail-domain interacts with the enhancer chro-
matin, including transcription factors and cofactors, while the middle- 
and head-domains form contacts with RNA Pol II and the pre-initiation 
complex at target promoters [8,18,19]. While the many subunits of 
Mediator can undergo extensive structural re-arrangements, the 
CDK8/19-module contains the only enzymatic activity of Mediator, 
namely the kinase CDK8 or its highly similar, but poorly studied, paralog 
CDK19 [9,21,22]. Completing the kinase module are: cyclin C (CCNC), 
and subunits MED12 and MED13. CDK8/19 activity appears restricted 
by its requirement for proper quaternary structure [23]. For full activity, 
CDK8/19 must associate simultaneously with cyclin C and with MED12, 
the latter embraces CDK8 allowing it to attain proper opening of its 
T-loop [23]. Evidence suggests that only CDK8, or CDK19, can occupy 
Mediator at one time, and the same is true for the paralog subunits 
MED12L and MED13L (reviewed elsewhere) [8,9,22]. Collectively, 
these may represent alternate combinations of the CDK8/19-module, 
providing opportunity for subtle modulation of Mediator function. 
The Mediator complex must associate with the many different tran-
scription factors that define an enhancer locus. This constitutes one arm 
of the Mediator bridge at the enhancer. Recent evidence hints at how 
this may be achieved. Mediator subunits in its tail sub-module have been 
shown to engage in a high number of low specificity and weak in-
teractions via phase separation, thereby achieving a “fuzzy” interaction 
between Mediator and the activation domains of many different tran-
scription factors [24–27]. The second arm of the Mediator bridge ex-
tends to interact with the pre-initiation complex, inducing the 
recruitment of RNA Pol II at target promoters [20] (Fig. 1). Compre-
hensive cryo-EM studies and in vitro biochemical assays have collec-
tively revealed how Mediator undergoes extensive structural 
re-arrangements to achieve this [8,9,18,19]. Notably, the 
CDK8/19-kinase module plays a key role, associating with 
core-Mediator and repressing RNA Pol II recruitment [8,9,18,19] (see 
below). In addition to its structural aspects, the Mediator bridge is dy-
namic and programmable, integrating many upstream signals [8,28]. 
Precisely how upstream signals modulate Mediator function is only 
Fig. 1. The Mediator complex integrates multiple 
signals and bridges enahcers to promoters to 
regulate pluripotent cell identity. Mediator acts as 
a central hub which links enhancers and target pro-
moters, integrates combinatorial signals, and recruits 
RNA Pol II, to guide the transcriptional program of 
cell identity. The core transcriptional machinery is 
shown simplified, within a phase-separated tran-
scriptional condensate (light green, membrane-less 
region). The largest enhancers, known as super- 
enhancers emerge by coalescing multiple smaller 
constituent enhancer regions (purple thick lines), 
each enriched in lineage-specifying transcription 
factors, histone marks, and chromatin regulators 
(indicated by small coloured circles). Mediator asso-
ciates with these many factors and receives upstream 
signaling inputs from pathways, including MEK-ERK. 
Mediator recruits RNA Pol II to the pre-initiation 
complex, a function which can be hindered by the 
CDK8/19 kinase-module, via structural or kinase- 
dependent activities of CDK8/19. In PSCs, the 2i in-
hibitor cocktail is known to rapidly alter the tran-
scriptional program to promote naïve pluripotency, of 
which, MEK-inhibition is the key feature. However, 
how MEK-inhibition resets the transcriptional ma-
chinery to the naïve program remains to be clarified. 
In PSCs, we find that MEK-inhibition leads to global 
up-regulation of enhancer activity via increased RNA 
Pol II recruitment. We find that the reorganization of 
the transcriptional machinery by MEK inhibition 
operates largely via controling the activity of CDK8/ 
19 downstream. In this way, both treatments induce a 
highly overlapping set of phospho-changes focused on 
the transcriptional machinery, hyper-activating en-
hancers and Mediator, triggering increased RNA Pol II 
recruitment, and promoting the transcriptional pro-
gram of naïve pluripotency.   
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recently emerging. Acetylation [29] and phosphorylation [10,30–33] of 
multiple sites and subunits of Mediator have been detected, implicating 
p300 acetyl-transferase activity, and the MEK-ERK pathway, as major 
inputs. 
4. CDK8/19: the sub-module of Mediator that represses RNA Pol 
II recruitment 
The CDK8/19-kinase module (CDK8/19-CCNC-MED12/L-MED13/L) 
associates with core-Mediator and plays a central role in the regulation 
of how Mediator recruits RNA Pol II during each transcription cycle [8,9, 
22]. The detailed mechanisms of how CDK8/19 operates during the 
transcription cycle remain to be fully understood [22,34], and the 
relative contribution of CDK8/19 kinase activity versus its 
kinase-independent structural effects are unclear. However, we and 
others have observed that the ultimate outcome of CDK8/19 
kinase-inhibition is increased recruitment of RNA Pol II by Mediator, 
and stimulation of transcription [10,35]. In the context of leukemia, this 
global hyperactivation of Mediator function results in cancer cell death 
[35]. Intriguingly, in pluripotent stem cells, we found that 
CDK8/19-inhibition and global hyperactivation of Mediator did not 
result in transcriptional dysfunction, instead, a coherent shift occurred 
in the transcriptional program, transitioning from one cell identity to 
another [10]. This raises the possibility of 
pharmacologically-modulating cell identity of non-cancer cells in a 
non-deleterious manner. 
As mentioned above, currently it is not possible to fully understand 
the mechanism of CDK8/19 during the transcription cycle. Nevertheless, 
it is useful to consider the temporal order of events when interpreting 
the literature, and we summarize the role of CDK8/19 below in this 
order. CDK8/19 can sterically hinder the initial approach of Pol II to the 
Mediator complex based on several data and crystal structures [18,19, 
36], and indeed, this was how CDK8 was first identified in yeast [37]. 
Thus, CDK8/19 must transiently vacate its initial position to permit 
Mediator-Pol II interaction [8,9,18,19,38]. In yeast, this process in-
volves CDK11-catalyzed phosphorylation of Mediator subunits MED4 
and MED27 [39]. Also, we and others have found that CDK8/19 can 
phosphorylate itself and several other Mediator subunits [10,30,[36] 
37], raising the possibility that the kinase activity of CDK8/19 may 
somehow influence its structural role hindering the approach of Pol II to 
the Mediator complex. In reciprocal, extensive Mediator structural 
rearrangements re-position CDK8/19 with respect to RNA Pol II [18,19, 
23]. 
Later in the transcription cycle, following recruitment of RNA Pol II 
to Mediator, the pre-initiation complex is completed, and CDK8/19- 
Mediator undergoes further structural re-arrangements to participate 
in the release of RNA Pol II into productive elongation [8,9,18,19]. 
CDK8/19 has been reported to phosphorylate RNA Pol II directly in vitro 
[36,37], and to affect Pol II-CTD phosphorylation in vivo [40–45]. Also, 
CDK8/19 is reported to phosphorylate and orchestrate the function of 
positive and negative elongations factors including NELF, DSIF, TFIIH 
and the super-elongation complex [8,9]. However, we suggest that these 
reported roles of CDK8/19-mediated phosphorylation in elongation may 
be to some extent redundant, gene-specific, and/or compensated by 
other kinases such as CDK7 and CDK9. In this regard, we and others have 
used potent CDK8/19 small molecule inhibitors where transcription is 
modulated but can still proceed and cells are viable [10,30,35,43–46]. 
Here, it is notable that while the other transcriptional CDKs, namely 
CDK7 and CDK9, play general roles positively promoting transcriptional 
elongation, the role of CDK8/19 appears more nuanced. Thus, while 
chemical inhibition of CDK7 and CDK9 are lethal, abolishing tran-
scription [47–49], CDK8/19 chemical inhibition appears to modulate 
the transcriptional program, triggering global hyperactivation of 
Mediator, and increased Mediator-RNA Pol II interaction [10]. 
In summary, CDK8/19 has an overall effect of repressing RNA Pol II 
recruitment and, thereby, CDK8/19 kinase inhibition increases 
recruitment of RNA Pol II by Mediator and stimulates global hyper-
activation of transcription of enhancer target genes [10,35]. 
5. Mediator, intrinsically disordered regions, and 
transcriptional condensates 
RNA Pol II is known to participate in discrete membrane-less protein 
aggregates previously described as transcription factories [50–52]. More 
recently, studies have elucidated how these factors efficiently 
co-segregate from the nuclear milieu based on a shared propensity for 
phase separation, leading to the term transcriptional condensates [24, 
25,50–53]. Mediator and several other protein elements of the tran-
scriptional machinery contain intrinsically-disordered regions (IDRs) 
that confer their phase separation [24,25,50,52–54]. Thus, IDRs act as 
biophysical addresses to localize each protein, and they contribute an 
essential structural component to stabilize the transcriptional conden-
sate. In particular, approximately half of Mediator’s 30-subunits contain 
conserved IDRs, including CDK8 and CDK19 [54]. This shift in our un-
derstanding has been essential to explain the efficient assembly and 
structural stability of transcriptional condensates, but also their dy-
namic flexibility to changes in signaling. Specifically, transcriptional 
condensates possess vulnerability to perturbation via sharp transitions 
in their phase separation [17], a regulatory feature conferring dual ca-
pacity to stably drive high gene expression, or dissolve rapidly, as 
required. The ability of transcriptional condensates to switch between 
formation or dissolution may be essential to rapid transcriptional 
changes [17,22,55]. Pluripotent cells contain a discrete number of 
particularly large condensates containing Mediator and RNA Pol II that 
are thought to correspond to SEs [45,47,48]. Post-translational modifi-
cations within protein IDRs have been shown to control transitions in 
phase separation [53]. Thus, given the central role of the 
CDK8/19-module for Mediator, we speculate that its kinase activity 
could affect the entry or exit of proteins into the condensates, or even the 
formation and dissolution of the condensates themselves. In support of 
this, we recently identified CDK8/19-dependent phosphosites in the 
Mediator subunit Med1-IDR domain in mouse PSCs [10], a particularly 
large IDR previously shown to play a crucial role in transcriptional 
condensates in mouse PSCs [50]. 
6. The naïve and primed PSC states reflect developmental stages 
Pluripotent stem cells (PSCs) transition between cell states in vitro 
which faithfully reflect developmental stages in the early embryo [1,2,6, 
7] (Fig. 2A–C). Culture conditions to shield mouse PSCs from 
extra-cellular differentiation stimuli involve chemical inhibition of MEK 
and GSK3 kinases with a two inhibitor cocktail known as “2i” [6,56]. 
Mouse PSCs cultured in 2i (referred to as “2i-naïve” cells) phenocopy the 
stable and homogenous state of undifferentiated naïve pluripotency 
which exists transiently in vivo around the E4.5 mouse pre-implantation 
embryo epiblast (Fig. 2A–C). In contrast, culture of PSCs with standard 
serum/LIF media, in the absence of 2i, triggers a shift in cell identity 
towards post-implantation epiblast, also known as the primed state, 
analogous to the mouse ~ E5.5–6.5 stage. It is important to clarify that 
in serum/LIF cells are more properly described as heterogenous, fluc-
tuating between the naïve and primed state [6]. Full primed identity is 
achieved in FGF/Activin media and this recapitulates the cellular 
identity of the E6.5 mouse embryo epiblast [1,6,7]. Importantly, PSCs 
can be maintained during long-term passage in each of these develop-
mental stages. Also, by simply changing the media to alter the signaling 
inputs to the transcriptional machinery, cells can be directed forward or 
reverse in developmental identity. In this way, PSCs provide a proto-
typical model of cellular plasticity, whose transcriptional program can 
be stabilized, extinguished or re-captured. Notably however, much re-
mains unclear regarding how changes in extrinsic stimuli reset the 
transcriptional machinery to a new program. 
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7. The transcriptional brain during cellular fate decisions in 
pluripotency 
Here we consider the transcriptional decision-making process. Cell 
identity is the aggregate outcome of the entire set of active enhancers in 
a cell at any one moment. During identity transitions, enhancers are 
activated and decommissioned individually. Thus, the events at each 
enhancer can be rapid (consistent with the sharp transitions conferred 
by phase separation), while the aggregate shift in cell identity (all active 
enhancers) appears relatively slower and incremental. We use as a 
model the developmental window of naïve-to-primed pluripotency, 
outlined above. Extensive analyses over the past ~15 years have shown 
how this path in embryos is followed in close parallel by PSCs in vitro [1, 
2,6,7]. Pluripotency first arises at ~ E3.5–4.5 in mice, and at this initial 
Fig. 2. A summary of CDK8/19 function in early embryo cell identity transitions. (A) Schematic overview of mouse early embryo development. Naïve PSCs can 
be isolated from the E4.5 epiblast, and they can retain this cell identity homogenously in vitro. Primed PSCs can be isolated from the E6.5 epiblast, and they can be 
maintained in the fluctuating and heterogenous primed state in vitro. The 2i inhibitor cocktail can stabilize naïve identity, and promote primed PSCs to transition into 
the naïve state. (B) Similar to small molecule 2i-treatment of PSCs in vitro, in the embryo, MEK-signaling is naturally repressed by down-regulation of the FGF 
receptor. We find that CDK8/19 kinase inhibition, by genetic or pharmacological methods, can phenocopy these effects of 2i: stabilizing naïve identity, and pro-
moting primed cells to transition into the naïve state. Interestingly, we observe that in the embryo, CDK8 activity appears to be naturally repressed, with down- 
regulation of CDK8 levels and decreased nuclear availability of its essential binding partner Cyclin C. The table below summarizes the developmental phenotypes 
observed by genetic- or pharmacological-inhibition of CDK8 in the mouse. (C) A summary of the molecular and morphological differences reported for naïve and 
primed pluripotent states. 
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boundary, cellular identity is very well defined in the naïve state, where 
cells are effectively deaf to developmental signals and lack any trace of 
differentiation programs. This is analogous to 2i-naïve PSCs in vitro [1,2, 
6,7,56,57]. Subsequently, cells progress through a gradient of interme-
diate pluripotency stages, where they gradually become receptive to 
differentiation stimuli, collectively referred to as being “primed” for 
development [1,2,6,7]. This period reflects mouse embryo epiblast 
development from E4.5–5.5. A multitude of studies have captured and 
defined specific intermediate states with PSCs in vitro, referring 
sequentially, for example, to formative, primed-like, epiblast-like, or 
rosette states [58] of pluripotency (thoroughly reviewed elsewhere [1,2, 
6,59]. However, now, and with the benefit of hindsight, we favour the 
idea that a continuum of pluripotency states exists, marked by incre-
mental changes in gene expression and other detailed molecular 
characteristics. 
Ultimately, around E5.5–6.5, mouse embryo epiblast cells exit from 
pluripotency, and choose between three competing transcriptional 
programs for lineage-specification, into one of the embryonic germ 
layers: ectoderm, mesoderm, and endoderm [1,6,7,60] (Fig. 3). This 
decision-making process remains to be fully understood, however evi-
dence suggests that while naïve cells possess a single homogenous un-
differentiated transcriptional program, cells in the primed stages begin 
to receive simultaneous and competing signals drawing them to activate 
lineage-specific transcriptional programs of one of the 3 germ layers 
[61–66] (Fig. 3). 
Crucially, lineage-specifying transcriptional programs attempt to 
reinforce themselves, and repress other competing programs [67–70]. 
The antagonistic and heterogenous behaviour of transcriptional pro-
grams within individual cells at this time is thought to represent a 
prototypical example of plasticity. Here, cells exist in a super-position, 
simultaneously expressing the early lineage-specifiers of opposing 
future fates [61–66]. Thus the cell population is also heterogenous; with 
individual cells expressing genes that suggest a moderate bias toward 
one or other fate. Such stochastic decision-making may have evolved to 
allow cells to sense and respond to diverse environmetal stimuli, 
ensuring that from one population of cells, three developmental fates 
emerge. In vivo, this is transient, and resolves in a few hours, with each 
cell choosing a single germ-layer program. In vitro, it is possible to 
capture this decision-making process, as a population of primed PSCs, 
with heterogenous and fluctuating gene expression programs, literally 
“priming” themselves to fully-activate ectoderm, mesoderm, or endo-
derm [1,2,6,7]. It is interesting to consider the events that occur at 
super-enhancers, and Mediator function, during this competition be-
tween transcriptional programs, as these processes may represent 
common features of many, if not all, transitions in cellular identity. For 
example, similar co-expression of competing lineage-specifiers has been 
observed in other fate decisions throughout development and regener-
ation [71,72]. Thus, the naïve-primed pluripotency window provides a 
model to elucidate the transcriptional basis of cell plasticity. The mo-
lecular lessons learned here are likely to apply to other fate decisions. 
8. The role of Mediator in pluripotent cell identity 
We recently hypothesized that manipulation of the transcriptional 
machinery during states of plasticity, might toggle cellular identity to-
ward one path or another. We chose PSCs in the naïve-primed pluripo-
tency window as our model of plasticity. As an actionable strategy, we 
began by targeting the transcriptional CDKs, CDK7, CDK8/19, and 
CDK9, since these kinases represent direct regulators of the transcrip-
tional machinery, they are amenable to pharmacological inhibition, and 
indeed, several highly selective small molecule inhibitors exist [10]. We 
found that selective inhibition of CDK7 and CDK9 produced a general 
inhibition of transcription, and was ultimately deleterious, consistent 
with their known general roles in RNA Pol II transcription. In contrast, 
small molecule kinase inhibition of CDK8/19 (CDK8/19i) produced a 
striking and characteristic shift in mouse PSC identity, from primed to 
naïve. 
We explored a possible mechanism, following the role of CDK8/19 as 
a transcriptional CDK, located within the Mediator complex [10]. Also, 
we compared the induction and stabilization of naïve pluripotency by 
CDK8/19i versus the well-characterized 2i inhibitor cocktail. 2i is 
highly-effective in mouse, but not in human PSCs [1,4,73,74], and the 
effects of 2i on the transcriptional machinery have not been explored. 
Importantly, we found that 2i-naïve and CDK8/19i-naïve mouse PSCs 
were highly similar according to their transcriptome and proteome [10]. 
Collectively, our data suggest that 2i and CDK8/19i rapidly induce a 
highly overlapping set of phospho-changes focused on the transcrip-
tional machinery (Fig. 1). We also found that Mediator activity was 
increased in 2i and CDK8/19i, consistent with a repressive role of 
CDK8/19 in the ability of Mediator to recruit RNA Pol II. Thus 2i and 
CDK8/19i triggered enhancer hyperactivation, global increase in RNA 
Pol II recruitment to promoters, and resetting of gene expression. This 
included the upregulation of enhancer-derived RNAs (eRNAs), and the 
resetting of endogenous retroviral and repeat element expression. In 
sum, the ability of 2i and CDK8/19i to induce naïve features appears to 
originate from their common effect on Mediator and RNA Pol II tran-
scriptional activity. This model is consistent with the concept that 
transitions in cell identity are driven by early reconfiguration of the 
active enhancer network, which resets the transcriptional machinery to 
the new program [14,67,70,75–77]. In summary, targeting Mediator 
through its kinase module selectively stabilizes an early pluripotent cell 
Fig. 3. Emergence and dissolution of transcriptional programs in the 
naïve to prime transition. A putative model of dominance and antagonism in 
transcriptional programs. Binary cell fate choices are common though devel-
opment and regeneration. In the case of the naïve-primed developmental 
window of pluripotency, global hyperactivation of enhancers and Mediator- 
recruitment of RNA Pol II produces a coherent outcome: up-regulation and 
stabilization of naïve epiblast identity. Here, we suggest a putative mechanism. 
In primed identity, cells are plastic and heterogenous due to co-existence of 
lineage-specifying transcriptional programs for forward development into the 3 
embryoinc germ layers, however, they are moderately expressed, antagonistic, 
and weakly established. Powerful naïve-specifiying transcription factors and 
super-enhancers have begun their decline, but are not yet decommissioned. 
Upon global hyperactivation of enhancers and Mediator-recruitment of RNA Pol 
II (by treatment with 2i or CDK8/19i), the naïve-specifiying transcription fac-
tors and super-enhancers become dominant, and suppress the nascent germ 
layer programs. 
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identity, repressing differentiation, favoring self-renewal, and 
up-regulating pre-implantation naïve epiblast gene expression patterns. 
As mentioned before, the induction of naïve identity using 2i or 
CDK8/19i treatments can stimulate Mediator function, which we detect 
by a global increase in RNA Pol II recruitment, global hyper-activation of 
existing mouse PSC enhancer loci, and upregulation of enhancer-driven 
transcription. We propose that this reinforces the pluripotency network 
underlying naïve PSC identity. In agreement with a recent report [78], 
we observe that in 2i, mouse naïve-specific enhancer activity is partially 
resistant to enhancer/Mediator destabilization by BRD4-inhibition. 
Importantly, this property can also be conferred by expression of 
CDK8-kinase dead mutant protein. This suggests a simple mechanism 
where removal of the inhibitory influence of CDK8/19, hyperactivates 
Mediator function at enhancers, and that this occurs similarly in 2i or via 
CDK8/19 inhibition. In support of global activation of super-enhancers 
in the naïve state, a recent study of chromatin looping has revealed 
that super-enhancers interact with more target promoters, and engage in 
more long-range interactions, during mouse naïve pluripotency 
compared to primed pluripotent cells [79], while furthermore, a state of 
global hyper-transcription has been suggested in PSCs [80,81]. Lastly, 
we note that the induction of naïve features in human PSCs was recently 
associated with a significant global increase in the enhancer mark 
H3K27ac, including at SEs [82]. These data may be consistent with our 
mechanistic insights, where CDK8/19 inhibition up-regulates enhancer 
activity, in particular at super-enhancers, thereby driving the stabiliza-
tion of naïve pluripotency. 
9. DNA methylation separates CDK8/19i from 2i 
As outlined above, CDK8/19i recapitulates a significant proportion 
of 2i-associated effects on mouse naïve cell identity, however, global 
DNA hypomethylation was an exception [10] (Fig. 4). The ability of 2i to 
trigger global DNA hypomethylation is thought to be due to the inhi-
bition of MEK signaling [1,83–87]. It is important to mention that 
transient DNA hypomethylation is a characteristic of embryonic naïve 
pluripotency at E4.5 [6]. However, both mouse and human 2i-naïve 
PSCs differ significantly in the genomic methylation pattern compared 
to pre-implantation epiblast cells [6,73]. Moreover, it has been reported 
that 2i-naïve mouse PSCs lose developmental potential after long-term 
passage [88,89]. This loss of developmental potential has been attrib-
uted to the continued inhibition of DNA methylation that resulted in 
chromosomal instability and loss of imprinting. Moreover, female cells 
turned out to be more sensitive to the long-term effects of MEK inhibi-
tion, consistent with the expression of MEK inhibitory factors from the 
two active X chromosomes. Transcriptional mechanisms have been 
proposed to connect MEK-inhibition with DNA demethylation, specif-
ically through upregulation of PRDM14, a transcriptional repressor of 
the DNA methyl-transferase DNMT3 gene family, and activity of the 
Tet-family of dioxygenases [83,84,86,87,90]. 
In contrast to 2i, CDK8/19i recapitulates the same transcriptional 
changes as 2i, but does not trigger global DNA hypomethylation [10] 
(Fig. 4). In CDK8/19i-naïve mouse PSCs, DNA methylation remains 
unchanged. We speculate that MEK inhibition must contribute to DNA 
demethylation through direct phosphorylation events, such as direct 
phosphorylation of DNMTs [91]. The DNA hypo-methylation following 
inhibition of MEK signaling was recently attributed to the 
down-regulation of UHRF1 protein levels, resulting in a failure to recruit 
DNMT1 to the replication fork for methylation maintenence [85]. We 
have confirmed that 2i (which includes MEK-inhibitor) leads to UHRF1 
down-regulation, and that this is associated with global DNA 
hypo-methylation as expected [10]. Interestingly, CDK8/19i treatment 
did not down-regulate UHRF1 protein levels, thus providing a likely 
mechanism to explain how CDK81/9i can preserve global DNA 
methylation [10]. The ability of CDK8/19i to implement naïve plurip-
otency, without global DNA hypomethylation, may avoid the detri-
mental side effects of imprint erasure recently reported during extended 
passage of mouse PSCs under conditions of MEK-inhibition [73,88,89]. 
Indeed, we have observed that mouse ES cells long-term adapted to 
CDK8/19i retain full developmental potential upon withdrawal of 
CDK8/19i, as demonstrated by mouse chimera generation assays, where 
highly chimeric off-spring developed to adulthood and achieved germ-
line transmission [10]. Since DNA hypo-methylation is part of the naïve 
stage of pluripotency and is required for normal development [92], the 
possibility remains that upon withdrawal of CDK8/19i and aggregation 
of the pre-treated PSCs within a developing blastocyst inner cell mass, a 
transient wave of DNA hypo-methylation may occur, permitting suc-
cessful development. 
10. Application of CDK8/19i for human pluripotency 
Species-specific differences exist between human PSCs and our prior 
understanding of pluripotency based on rodent models [1,5]. In 
particular, while 2i treatment has a dramatic efficiency in stabilizing 
naïve features in mouse PSCs, 2i-based media cocktails generally pro-
duce extensive cell death during adaption of human and primate PSCs, 
and are associated with impaired developmental capacity [4,73]. 
Importantly, CDK8/19i upregulates and stabilizes multiple features of 
the naïve state in human PSCs, with minimal cell death, shifting the 
identity of all cells gradually. Cultivation of human PSCs in the presence 
of a chemical inhibitor of CDK8/19 is sufficient to recapitulate the 
majority of molecular characteristics associated with a transition from 
the primed to the naïve state. Other molecular features associated with 
the more naïve end of this spectrum in human naïve PSCs include SSEA4 
down-regulation [73]. However, SSEA4 down-regulation may not be a 
strict requirement, since there are chemical cocktails that induce a naïve 
state in human PSCs withouth downregulating SSEA4 [4,93]. Similarly, 
CDK8/19i also installs naïve features in human PSCs while maintaining 
SSEA4 (Fig. 4). 
11. CDK8/19i-naïve human pluripotent cells retain long-term 
developmental potential 
Stabilization of the human naïve pluripotent state in vitro has proven 
to be challenging and remains to be optimized [73,74,94]. In particular 
the genomic instability and loss of imprinting observed with 2i-induc-
tion of induce naïve features are associated with striking loss of devel-
opmental potential in human PSCs [73,94,95]. This includes inability, or 
heavy bias, in forming all 3 embryonic germ layers upon differentiation, 
for example in embryoid body or teratoma assays, which are normally 
straight-forward methods for primed human PSCs to express their 
Fig. 4. Unified model of 2i and CDK8/19i naïve pluripotency. A summary 
of the signaling hierarchy between MEK, CDK8/19-kinase, and Mediator. A 
large proportion of the effect of MEK signaling channels through CDK8/19- 
Mediator to affect the transcriptional program of cell identity. CDK8/19- 
independent effects of MEK inhibition that we have identified include global 
DNA hypo-methylation in mouse and human PSCs, specification of the primi-
tive endoderm in the mouse pre-implnatation blastocyst, and, in human PSCs, 
SSEA4 down-regulation. 
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developmental potency. All this is probably caused, as in mouse, by 
MEKi-driven DNA demethylation. Indeed, 2i-naïve human PSCs present 
reduced global methylation, however, the methylation patterns differ 
significantly from the methylation pattern in pre-implantation epiblast 
cells [73]. 
Similar to our observations in mouse PSCs, CDK8/19i does not 
induce MEK-inhibition or global DNA hypo-methylation in human PSCs 
[10]. Accordingly, multiple CDK8/19i-naïve human PSCs preserved a 
normal karyotype after >16 passages [10]. Importantly, upon removal 
of CDK81/9i chemical inhibition, full developmental potency is main-
tained [10]. Specifically, following prolonged adaption to CDK8/19i, 
human PSCs could develop into all three embryonic germ layers in 
embryoid body and teratomas assays. Moreover, CDK8/19i-pre-treated 
human PSCs displayed clonal survival and low level chimerism in 
human-rabbit blastocyst interspecies assays [10]. Altogether, these data 
suggest that the role of CDK8/19 in pluripotency is conserved in mouse 
and human, and therefore perhaps across mammalian species. 
12. The CDK8/19-kinase during early development 
Since CDK8/19 kinase inhibition favours up-regulation of naïve 
pluripotency in vitro, we have explored the possible role of CDK8/19 in 
the embryo, where the naïve state arises naturally in the absence of 
chemical inhibitors [10] (Fig. 2A). Firstly, we found that CDK8 mRNA 
and protein expression is ~5×–20× fold higher than CDK19 in mouse 
and human early embryo development up to day ~ E6.5, suggesting that 
CDK8, rather than CDK19, is the major player at this stage. Thus we 
focused on CDK8 function across early mouse embryonic development 
(Fig. 2B), and its role may be summarized in three periods [10]:  
(i) CDK8 is required during 1C to morula development, where its 
expression is high. In support of this, CDK8-knockout is embry-
onic lethal before the 4C stage [96], and CDK8/19i blocked 
development at the 2C stage [10].  
(ii) During morula to blastocyst pre-implantation development, 
CDK8 and cyclin C expression declines. This coincides with the 
emergence of the E4.5 pre-implantation naïve epiblast and, 
accordingly, small molecule CDK8/19i does not interfere with 
naïve epiblast specification [10]. Also, in contrast to MEK inhi-
bition, CDK8/19i does not affect the epiblast/primitive endo-
derm (EPI/PE) lineage segregation [10] (Fig. 4). In agreement, 
CDK8-knockout starting in ~E3.5 embryos permitted naïve 
epiblast specification, and EPI/PE segregation [97]. Specification 
of the PE is highly sensitive to MEK inhibition [98–100]. The 
phosphorylation of the transcription factor GATA6 by MEK has 
been recently shown to be a key event in the determination of the 
PE [101]. Since CDK8/19i does not affect the kinase activity of 
MEK [10], it is possible that the presence of an active MEK/-
GATA6 circuit is sufficient to determine PE formation in the face 
of CDK8/19 inhibition.  
(iii) During the subsequent developmental transition of pre- 
implantation naïve epiblast to the post-implantation primed 
state, CDK8 expression becomes increased and its activity is 
required for the morphogenic events during this transition [10]. 
Moreover, genetic evidence has very recently emerged of an 
essential role for CDK8 in post-implantation development around 
~ E5.5-E10.5 [97], and we speculate that here upstream signals 
such as FGF-MEK-ERK may guide CDK8 function (as discussed 
below in the section on MEK signaling). Therefore, overall, CDK8 
function in early embryonic development mirrors its expression 
pattern (Fig. 2B), with elevated expression and essential roles at 
the 1–2C stage and during post-implantation development, In 
contrast, between these periods, a physiological minima in CDK8 
expression and function exists around E4.5 that equates to naïve 
PSCs in vitro [10]. In sum, we conclude that the physiological 
minimum in CDK8 function coincides with the emergence of 
naïve pluripotent epiblast identity in vivo, a feature which can be 
exploited to stabilize naïve PSC culture by CDK8/19i in vitro. 
In further support of these data, mouse PSCs are known to include an 
additional form of transcriptional heterogeneity involving infrequent, 
but dramatic and transient, re-activation of the gene expression program 
of the 2C embryo stage [102–104]. It has been shown that 2i treatment 
represses this 2C fluctuation [102,104], and we have confirmed that 
CDK8/19i also represses this additional example of transcriptional het-
erogeneity [10]. We suggest an analogy between the high expression 
and developmental requirement for CDK8 in the 2C embryo stage, and 
repression of the 2C transcriptional fluctuation in mouse PSCs by 
CDK8/19i. 
13. A signaling hierarchy: CDK8 inhibition downstream of MEK 
inhibition 
Better understanding of the downstream signaling from MEK-ERK, 
and how it links to the transcriptional machinery, may improve our 
control over cellular plasticity and aide stabilization of cell identity ex 
vivo. The high degree of overlap in phospho-changes and RNA Pol II 
regulation induced by 2i and CDK8/19i kinase inhibitors immediately 
suggests that these chemical inducers of the naïve state might operate 
within the same pathway [10]. Importantly, analysis of kinase activity 
has implied a signaling hierarchy (Figs. 1 and 4), where 2i treatment 
decreases CDK8/19 kinase activity, yet CDK8/19i has no effect on 
MEK-mediated phosphorylation of ERK. Thus, downstream of MEK-ERK 
signaling, CDK8/19 activity is down-regulated, explaining how 2i and 
CDK81/9i treatments functionally overlap in the control of Mediator 
and the transcriptional machinery [10]. 
Significant evidence supports the direct input of MEK-ERK signaling 
into Mediator and the control of the core transcriptional machinery in 
PSCs. Consistent with this model, it has been recently reported that MEK 
signalling during exit from the naïve state, directly or indirectly, results 
in phosphorylation of Mediator subunits and alter eRNA transcription 
within PSC super-enhancers [32]. All current PSC media cocktails that 
stabilize the naïve state contain small molecule inhibitors targeting one 
or more factors in the MEK signalling pathway (FGFRi, RAFi, SRCi, PKCi, 
p38i, JNKi, MEKi) [1]. It is notable that many components of the MEK 
pathway have also been shown to regulate CDK8 activity, including 
KRAS, RAF, SRC, PKC, p38, JNK, MEK, and ERK [105–108]. Thus, 
CDK8/19-inhibition may be a common feature of media cocktails for 
stabilizing PSCs in the naïve state. Further studies are required to reveal 
the precise mechanism by which MEK-ERK signaling regulates CDK8/19 
activity in PSCs. 
14. Model: dominant programs resolve transcriptional decisions 
in cell identity 
A better understanding of the intracellular competition between 
transcriptional programs may apply widely to human disease. In this 
regard, global enhancer hyperactivation was recently identified as a 
common feature across all human cancers tested [109], while addiction 
to globally up-regulated transcription also appears to be a unifying 
aspect of cancer [110]. Using the model of PSCs to study these phe-
nomena, we observe that following exposure to 2i or CDK8/19i, the 
trans-activating potential of existing enhancers and Mediator complexes 
become globally hyper-activated [10]. This raises an important ques-
tion: why is the naïve pluripotent state favoured by global enhancer/-
Mediator hyperactivation? A general feature of lineage-specifying 
transcription factors is that they act to promote their own lineage, but 
repress alternative fates. This is known to also apply for the transcription 
factors that specify for the 3 embryonic germ layers as cells exit plu-
ripotency [61–66,111–113]. For example, the pluripotency factors 
OCT4 and SOX2 are known to repress ectodermal- and 
mesendodermal-lineage enhancers, respectively [65,99,111–113]. 
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Within individual primed cells, these lineage-specifying gene expression 
programs are in competition with each-other, and they are also 
moderately expressed and not fully established. Indeed, there is evi-
dence that nascent germ layer programs rely on relatively weak en-
hancers which are not yet fully established [70,82,114,115], while the 
naïve enhancers retain a capacity to rapidly return to full strength, 
retaining their plasticity [10]. Thus, upon global hyperactivation of 
enhancers by 2i or CDK8/19i, the naïve program becomes dominant, 
quickly suppressing forward differentiation of the nascent germ layer 
programs (Fig. 3). In this way, the transcriptional landscape of naïve 
pluripotency can be up-regulated, establishes dominance, and remains 
stabilized, by Mediator stimulation, and this can be directly achieved by 
chemical inhibition of CDK8/19 [10]. 
15. Other applications of Mediator stimulation via CDK8/19i 
We note that a similar mechanism of Mediator hyperactivation via 
CDK8/19 inhibition has been reported in cancer cells [35]. However, 
intriguingly, this resulted in cell death in acute myeloid leukemia (AML) 
cells [35], while we find that a similar approach in PSC reinforces naive 
cell identity [10]. Cancer cells commonly develop novel oncogenic SEs 
[110,116,117] that can result in addiction to a defined range of 
enhancer-driven transcription. Thus cancer cell oncogenic SEs may be 
sensitive to perturbation, either when hyperactivated, as in the case of 
CDK8 inhibition [35], or when inhibited, as in the case of BRD4 inhi-
bition [78]. This provides an interesting parallel with MEK inhibition, 
which is also detrimental to many cancer cells, but is beneficial to the 
naïve state. 
Binary fate decisions are common throughout development and 
regeneration. We speculate that other cell fate decisions may operate via 
processes in the transcriptional machinery similar to the naïve-primed 
pluripotency equilibrium. Thus, we suggest that other examples of 
CDK8/19i influencing cell identity may exist. Recently, CDK8/19-kinase 
inhibition was found to produce an anti-inflammatory effect in mouse 
tissues. This was attributed to the ability of genetic and small molecule 
CDK8/19-inhibition to promote the production of immuno-suppressive 
regulatory T cells (T-regs) from their progenitor population of naïve T 
cells [118–120]. We hypothesize that this process may operate, at least 
in part, through hyper-activation of enhancers, biasing the outcome of 
naïve T-cell differentiation toward the production of T-reg cells. It will 
be interesting to apply CDK8/19i and global hyperactivation of en-
hancers and Mediator in other examples of cellular plasticity to toggle 
cell fate, where each system may display a naturally dominant fate. 
16. Conclusions 
Mediator is a central hub (Fig. 1) which we can target pharmaco-
logically using small molecule inhibition of CDK8/19. CDK8/19i 
removes a repressive influence from Mediator function, effectively 
triggering hyperactivation of enhancers via the ability of Mediator to 
more efficiently recruit RNA Pol II [10]. In vitro, we identify that 
CDK8/19i shifts the equilibrium between naïve and primed pluripotent 
states, favouring naïve features in mouse and human pluripotent cells 
(Fig. 2). In vivo, we observe CDK8 down-regulation in the E4.5 epiblast, 
coinciding with the natural emergence of the naïve pluripotent state 
(Fig. 2). Thus CDK8 down-regulation in vivo appears to parallel the 
ability of CDK8/19i to stabilze the naïve state in PSCs in vitro. 
The effects of CDK8/19i are not dependent on direct MEK-inhibition 
and this has the advantage of avoiding some deleterious effects of MEK- 
inhibition such as DNA hypo-methylation and genomic instability in 
PSCs [10] (Fig. 4). Nevertheless the majority of the other effects of 
MEK-inhibition can be phenocopied by CDK8/19i10. Thus, current evi-
dence suggests that the control of CDK8/19 activity lies downstream of 
MEK-ERK signaling (Fig. 4). Further studies are required to reveal pre-
cisely how MEK-ERK signaling regulates CDK8/19 activity in PSCs. 
However, we suggest this model to explain how CDK8/19-inhibition can 
recapitulate many, but not all, molecular events typically observed 
during the induction of the naïve state downstream of MEK inhibition. 
Thus chemical inhibition of CDK8/19 offers a new approach that may 
help to solve remaining challenges in human naïve PSC culture associ-
ated with direct MEK-inhibition [10]. 
Molecular analyses reveal how the RNA Pol II transcriptional ma-
chinery is reorganized by CDK8/19i to coordinate cell identity conver-
sion [10]. In the primed state, multiple lineage-specifiying transcription 
programs are in competition, and we suggest that CDK8/19i resolves 
this by up-regulating enhancers and forcing one dominant program to 
suppress the others (Fig. 3). In this way, heterogenous gene expression 
constituting a plastic cell state, is resolved into a single homogenous 
expression program and a stable cell identity. This may reveal insights 
into how the transcriptional machinery resolves other cell fate decisions, 
and surprisingly, how it can be directly manipulated to produce a 
coherent outcome, favouring one local cell identity over others. We 
hypothesize that CDK8/19i may similarly toggle between cell fate out-
comes in other systems of cellular plasticity. Indeed, there is some evi-
dence to support this in AML cancer cells, and in T cell differentiation 
pathways in vivo. 
The extent to which CDK8/19i mimics 2i suggests a central role of 
Mediator during the induction of naïve pluripotency, and it provides a 
mechanism by which naïve pluripotency may arise in vivo [10]. Lastly, 
chemical inhibition of CDK8/19 may help to stabilize other intrinsically 
unstable cell states, and it will be of interest to transfer these principles 
to other contexts of cellular plasticity. 
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